Cargando…

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

BACKGROUND: TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC). Internal review of data at a single-institution showed a trend towards bett...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasi, Pashtoon M., Kotani, Daisuke, Cecchini, Michael, Shitara, Kohei, Ohtsu, Atsushi, Ramanathan, Ramesh K., Hochster, Howard S., Grothey, Axel, Yoshino, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944251/ https://www.ncbi.nlm.nih.gov/pubmed/27412464 http://dx.doi.org/10.1186/s12885-016-2491-y

Ejemplares similares

Difference in Neutropenia due to Administration Schedule of TAS-102
por: Yoshida, Yoichiro, et al.
Publicado: (2017)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
por: Doi, T, et al.
Publicado: (2012)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
por: Chen, Duke, et al.
Publicado: (2018)

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
por: Conti, Matteo, et al.
Publicado: (2023)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
por: Watanabe, Daichi, et al.
Publicado: (2023)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

Drug-induced Pneumonitis Following the Administration of TAS-102
por: Hasegawa, Yoshikazu, et al.
Publicado: (2016)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab
por: Tamaki, Sawako, et al.
Publicado: (2022)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study
por: Wang, Cassia B., et al.
Publicado: (2019)

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
por: Bendell, Johanna C., et al.
Publicado: (2016)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases
por: Fidelman, Nicholas, et al.
Publicado: (2022)

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
por: Van Cutsem, Eric, et al.
Publicado: (2017)

Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
por: Kamei, Hideki, et al.
Publicado: (2016)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
por: Lara-Morga, Celia, et al.
Publicado: (2023)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
por: TANAKA, NOZOMU, et al.
Publicado: (2014)

Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine
por: Baba, Yuji, et al.
Publicado: (2017)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)
por: Yoshida, Yoichiro, et al.
Publicado: (2019)

Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
por: Shahjehan, Faisal, et al.
Publicado: (2019)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2015)

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
por: Nagatani, Yoshiaki, et al.
Publicado: (2016)

Refractory Thrombocytopenia and Neutropenia: a Diagnostic Challenge
por: Gyan, Emmanuel, et al.
Publicado: (2015)

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
por: Cleary, James M., et al.
Publicado: (2017)

Shieldings: TAS
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_q9oeqlhp4nlvhc62t01ougt4ms